Market Snapshot

S&P Futures
4,226.75
Dow Futures
34,713.00
NASDAQ Futures
13,715.50

1.66$-0.02 -1.19%
pre market     21:21:44 pm   
From: To:

Stock Snapshot

1.66
Prev. Close
1.65
Open
Market Cap
Number of Shares
1.6200
Day Low
1.6700
Day High
1.66
-
P/E Ratio
Free Float in %
-
EPS 2021
-
Book Value per Share
-
Cash Flow per Share
Seneca Biopharma, Inc. (SNCA)
Seneca Biopharma, Inc. (SNCA) stock rallied over -1.19% intraday to trade at $1.66 per share on NASDAQ. The stock opened with a fall of -0.60% at $1.65 and touched an intraday high of $1.6700, rising 0.60% against the last close of $1.66. The stock went to a low of $1.6200 during the session.

Historical Prices

DateOpenCloseAdj. CloseDaily HighDaily LowVolume
2021-04-27$1.65$1.66$1.66$1.67$1.621,109,000
2021-04-26$1.78$1.68$1.68$1.88$1.605,647,500
2021-04-23$1.58$1.58$1.58$1.70$1.542,277,400
2021-04-22$1.54$1.57$1.57$1.60$1.51841,200
2021-04-21$1.46$1.57$1.57$1.59$1.45513,800
2021-04-20$1.55$1.48$1.48$1.59$1.44775,000
2021-04-19$1.38$1.55$1.55$1.56$1.381,209,700
2021-04-16$1.40$1.39$1.39$1.42$1.34954,900
2021-04-15$1.50$1.42$1.42$1.59$1.411,463,500
2021-04-14$1.44$1.51$1.51$1.58$1.44884,600
2021-04-13$1.49$1.49$1.49$1.50$1.41948,400
Seneca Biopharma, Inc.
20271 Goldenrod Lane
Suite 2024
Germantown, MD 20876
United States

http://www.senecabio.com
301-366-4841
Employees
5
Sector
Healthcare
Sales or Revenue
Industry
Biotechnology
5Y Sales Change
-
Fiscal Year Ends
-
Dr. Kenneth C. Carter
Exec. Chairman & CEO
Dr. Matthew W. Kalnik Ph.D.
Pres & COO
Dr. Karl Y. Johe
Co-Founder
Seneca Biopharma, Inc.
Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidates include NSI-189, a chemical entity, which has been completed Phase II clinical trials for the treatment of major depressive disorder; and NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.